Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. (2022)
Attributed to:
Syndromic infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2352-4642(21)00305-9
PubMed Identifier: 34843669
Publication URI: http://europepmc.org/abstract/MED/34843669
Type: Journal Article/Review
Volume: 6
Parent Publication: The Lancet. Child & adolescent health
Issue: 1
ISSN: 2352-4642